Zoledronic acid concurrent with either high- or reduced-dose palliative radiotherapy in the management of the breast cancer patients with bone metastases: a phase IV randomized clinical study

被引：0
|
作者：
Lale Atahan
Ferah Yıldız
Mustafa Cengiz
Bunyamin Kaplan
Metin Özkan
Gozde Yazici
Mete Gündoğ
Ayfer Haydaroğlu
Aylin F. Korcum
Meriç Şengöz
Maktav Dinçer
Müge Akmansu
Kayıhan Engin
Mutlu Hayran
机构：
[1] Hacettepe University,Department of Radiation Oncology
[2] Erciyes University,Department of Radiation Oncology
[3] Ankara Education and Investigation Hospital of Ministry of Health,Department of Radiation Oncology
[4] Ege University,Department of Radiation Oncology
[5] Akdeniz University,Department of Radiation Oncology
[6] Marmara University,Department of Radiation Oncology
[7] İstanbul University,Department of Radiation Oncology
[8] Gazi University,Department of Radiation Oncology
[9] Uludağ University,Department of Radiation Oncology
[10] Anadolu Sağlık Merkezi,Department of Preventive Oncology
[11] Hacettepe University,undefined
来源：
Supportive Care in Cancer | 2010年 / 18卷
关键词：
Bone metastasis; Breast cancer; Radiotherapy; Zoledronic acid;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：691 / 698
页数：7
相关论文
共 50 条
  • [31] Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy
    Clemons, Mark J.
    Dranitsaris, George
    Ooi, Wei S.
    Yogendran, Geetha
    Sukovic, Tatjana
    Wong, Betty Y. L.
    Verma, Sunil
    Pritchard, Kathleen I.
    Trudeau, Maureen
    Cole, David E. C.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (30) : 4895 - 4900
  • [32] A phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal related event (SRE) or progressive bone metastases (BM) despite standard bisphosphonate (BP) therapy
    Clemons, M.
    Dranitsaris, G.
    Ooi, W. S.
    Yogendran, G.
    Sukovic, T.
    Wong, B. Y. L.
    Verma, S.
    Pritchard, K.
    Trudeau, M.
    Cole, D. E. C.
    BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 (03) : 342 - 342
  • [33] A double-blind, randomized study of denosumab versus zoledronic acid for the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma
    Henry, D.
    von Moos, R.
    Vadhan-Raj, S.
    Hungria, V.
    Spencer, A.
    Hirsh, V.
    Wang, J.
    Jun, S.
    Yeh, H.
    Dansey, R.
    EJC SUPPLEMENTS, 2009, 7 (03): : 12 - 12
  • [34] Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma
    Henry, David H.
    Costa, Luis
    Goldwasser, Francois
    Hirsh, Vera
    Hungria, Vania
    Prausova, Jana
    Scagliotti, Giorgio Vittorio
    Sleeboom, Harm
    Spencer, Andrew
    Vadhan-Raj, Saroj
    von Moos, Roger
    Willenbacher, Wolfgang
    Woll, Penella J.
    Wang, Jianming
    Jiang, Qi
    Jun, Susie
    Dansey, Roger
    Yeh, Howard
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (09) : 1125 - 1132
  • [35] Pain Outcomes in a Randomized Phase 3 Clinical Trial of Denosumab Vs Zoledronic Acid (ZA) in Patients With Solid Tumours and Bone Metastases
    Fallowfield, L.
    von Moos, R.
    Patrick, D.
    Cleeland, C. S.
    Henry, D. H.
    Hirsh, V.
    Zarogoulidis, K.
    Ying, W.
    Cong, Z.
    Yeh, H.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S485 - S485
  • [36] Randomised study of single dose (8 Gy vs. 6 Gy) of analgesic radiotherapy plus zoledronic acid in patients with bone metastases
    Ana Mañas
    Francesc Casas
    Juan P. Ciria
    Concha López
    Juan Sáez
    Amalia Palacios
    Manuel de las Heras
    Carmen Porto
    Elena Sánchez
    Carmen Martín
    Ricardo Esco
    Camilo Veiras
    José C. Martínez
    Magdalena Márquez
    Alfedo Ramos
    Felipe Calvo
    Javier Fuertes
    Francisco J. Andreu
    Jorge Contreras
    Leopoldo Pérez
    Jesús Romero
    Jordi Vayreda
    Concepción Victoria
    Clinical and Translational Oncology, 2008, 10 : 281 - 287
  • [37] Randomised study of single dose (8 Gy vs. 6 Gy) of analgesic radiotherapy plus zoledronic acid in patients with bone metastases
    Manas, Ana
    Casas, Francesc
    Ciria, Juan P.
    Lopez, Concha
    Saez, Juan
    Palacios, Amalia
    de las Heras, Manuel
    Porto, Carmen
    Sanchez, Elena
    Martin, Carmen
    Esco, Ricardo
    Veiras, Camilo
    Martinez, Jose C.
    Marquez, Magdalena
    Ramos, Alfedo
    Calvo, Felipe
    Fuertes, Javier
    Andreu, Francisco J.
    Contreras, Jorge
    Perez, Leopoldo
    Romero, Jesus
    Vayreda, Jordi
    Victoria, Concepcion
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2008, 10 (05): : 281 - 287
  • [38] A randomized phase III trial of denosumab versus zoledronic acid in patients with bone metastases from castration-resistant prostate cancer
    Fizazi, K.
    Carducci, M. A.
    Smith, M. R.
    Damiao, R.
    Brown, J. E.
    Karsh, L.
    Milecki, P.
    Wang, H.
    Dansey, R. D.
    Goessl, C. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (18)
  • [39] Similar reductions in bone turnover markers with oral ibandronate and intravenous (IV) zoledronic acid for bone metastases from breast cancer:: Phase III trial results.
    Body, J
    Lichinitser, M
    Tjulandin, S
    Garnero, P
    Bergström, B
    JOURNAL OF BONE AND MINERAL RESEARCH, 2005, 20 (09) : S118 - S118
  • [40] Economic evaluation of intravenous (IV) zoledronic acid vs. other IV bisphosphonates in the prevention of bone complications in breast cancer patients with bone metastases: A UK budget impact analysis
    Botteman, M
    Aapro, M
    Hay, JW
    Stephens, J
    Brandman, J
    VALUE IN HEALTH, 2005, 8 (03) : 344 - 344
12345